Bisphosphonates are currently used more often in patients with cancerous bone metastases, and their main effects are to inhibit bone destruction, relieve bone pain, reduce the incidence of bone-related events (fractures, paraplegia, etc.), and may have the effect of prolonging patients’ survival time, which has yet to be studied in a large randomized controlled sample, but there is no doubt that bisphosphonates play a very significant role in improving the quality of life of patients with cancerous bone metastases. Zoledronic acid is commonly used in the clinic as a monthly injection, and during its use some patients have been found to have certain non-specific symptoms that may be caused by the drug, but most of them do not require special management. The more common ones are flu-like symptoms, such as fever, mostly low fever, occasionally patients with high fever, which need active symptomatic treatment. In addition, malaise, generalized skeletal muscle aches and pains, nausea, decreased appetite, conjunctivitis are also encountered in the first use, and it is not necessary to be too nervous to encounter these conditions, which can be mostly self-healed, not necessarily due to the progression of the disease, if the symptoms are aggravated by repeated use, they can be observed after stopping the drug, and seriously affect Patients whose quality of life is seriously affected need to stop using it. Because most of zoledronic acid is excreted by the kidney, it is necessary to encourage more water intake and to clarify the renal function every time it is used. Zhao Qiang, Department of Urology, Peking University Cancer Hospital